India is in the “ tapering phase” of the alternate Covid-19 surge but the situation shouldn’t be taken for granted, the country’s Covid Task Force chief VK Paul has said in a discussion with CNBC-TV18 The Covid-19 count has been stabilising. It looks like we ’re in the tapering phase of the alternate surge. Still, given the experience of the alternate surge, we ca n’t take anything for granted,” said Paul on Monday Sounding caution, Paul also expressed solicitude for Mizoram due to the rising Covid-19 figures, saying there were some countries where the positivity rate is still high.
On the question of vaccines, Paul said workers were being trained to administer ZyCoV-D vaccine and that pricing issues are being reused. “ Pricing issues are still a work in progress for ZyCoV-D. Workers are being trained to administer the vaccine,”he added Presently, three vaccines-Covishield, Covaxin and Sputnik V- being administered in the country are only for those above 18 times of age. All of them are two- cure vaccines. Zydus Cadila’s indigenously developed needle-free Covid-19 vaccine ZyCoV-D is set to come the first vaccine that will be available in India for those in the age group of 12-18 times. It has entered Emergency Use Authorisation (EUA) Laying out the Centre’s plans, he said the top precedence is to vaccinate all grown-ups. “ We’re awaiting final instrument on Covaxin for children,”he said, adding that the Centre is exploring totally vaccinating children withco-morbidities.
An expert panel of India’s central medicine authority has recommended granting EUA to Bharat Biotech’s Covaxin for children and adolescents in the 2-18 times age group with certainconditions.However, it’ll be the alternate vaccine after ZyCoV-D to get EUA for use among those below 18 times, If approved by the Medicines Controller General of India (DCGI). The National Technical Advisory Group on Immunisation (NTAGI) is looking at how ZyCov-D should be deposited for utmost optimum use.
0
0
